Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Canopy Growth Corp (CGC) vs Celestica Inc (CLS) Price & Performance

Canopy Growth CorpTrade
Celestica IncTrade

Price performance (Past 24H)

Key statistics

Canopy Growth Corp vs Celestica Inc — how do they compare? Canopy Growth Corp trades at $0.97 (market cap $398.46M), while Celestica Inc trades at $347.6 (market cap $39.28B). The key difference: Celestica Inc is far larger — about 98.6× Canopy Growth Corp's market cap, and Celestica Inc is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.

CGCCLS
Market Cap
$398.46M$39.28B
Sector
HealthTechnology
52-Week High
$1.92$472.40
52-Week Low
$0.86$156.91
Enterprise Value
$337.90M$39.68B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Canopy Growth Corp

Canopy Growth (CGC) trades at $0.96, down 1.15% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses against expectations. Cash flow remains negative, but the balance sheet shows improving debt-to-asset ratios, down to 33.13% in 2025 from 53.61% in 2023.

The outlook is cautious; while cost-cutting and restructuring efforts are underway, profitability remains elusive, and the stock faces risks including potential delisting due to low share price. Analyst sentiment is divided, with 33% recommending buy, 41% hold, and 26% sell. Investors should weigh the potential for a turnaround against significant operational and regulatory challenges in the cannabis sector.

Celestica Inc

Celestica (CLS) trades at $345.18, down 4.08% over 24 hours, with technical indicators showing a bearish trend near key support at $339. The company demonstrates strong fundamentals with Q1 2026 EPS of $2.16 beating estimates, revenue growth accelerating to 55.55% YoY, and a robust ROE of 52.45%. Recent leadership appointments and raised FY2026 revenue guidance to $19 billion reflect operational momentum amid AI and data center demand tailwinds.

Wall Street maintains a bullish outlook with 63% buy ratings and a $440.10 consensus price target, implying 27% upside. Key risks include competitive pressures in the EMS sector and execution challenges in margin expansion. The stock's high P/E of 41.82 warrants monitoring, but earnings beats and institutional confidence support a positive investment case pending Q2 results on July 28, 2026.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Canopy Growth Corp

Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.

Read more on CGC

About Celestica Inc

Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.

Read more on CLS